Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Pfizer

Unusual Put Option Activity in Pfizer Stock - Have Investors Turned Bearish?

Barchart reports that Pfizer stock is showing unusual put option activity in yesterday's trading. Does that mean investors have turned bearish? Not necessarily, especially given the company's upgraded guidance.

Barchart

FDA approves updated COVID-19 shots but limits access for some kids and adults

The Food and Drug Administration has approved updated COVID-19 vaccines for the upcoming fall and winter season

The Independent UK

Trump Administration Plans To Pull COVID-19 Vaccines Off Market 'Within Months'

The Trump administration is preparing to remove COVID-19 vaccines from the U.S. market "within months," according to a close associate of Health and Human Services Secretary Robert F. Kennedy Jr.

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

Pediatricians’ association recommends COVID-19 vaccines for toddlers and some older children, breaking with CDC guidance

For 30 years, vaccine recommendations from the Centers for Disease Control and Prevention have aligned closely with those from the American Academy of Pediatrics, or AAP. But on Aug. 19, 2025, the AAP published new vaccine recommendations that diverge from those of the CDC.

The Conversation

3 Defensive Stocks That Can Weather Any Recession

Dividend stocks are often considered safe haven or defensive stocks that can safeguard a portfolio in turbulent times.

Barchart

Pfizer's Investigational Drug Flunks Late-Stage For Sickle Cell Disease

Pfizer Inc. (NYSE:PFE) on Friday released results from the Phase 3 THRIVE-131 study evaluating inclacumab, an investigational P-selectin inhibitor, in patients 16 years of age and older with sickle cell disease.

Benzinga

3 Long-Term Dividend Buys You Can Get for Under $50

Discover three undervalued dividend stocks under $50 that offer income, growth potential, and strong total returns for value investors

MarketBeat

Read news from The Economist, FT, and more,
with one subscription

Pfizer Raises Its Guidance and Analysts Up Their Targets - PFE Stock Looks Cheap

Pfizer stock is incredibly cheap following management's raise of its 2025 adjusted earnings per share guidance. It's at just over 8x this year's estimates and 7.8x next year. That's too cheap. Shorting puts works here.

Barchart

Merck, Pfizer-Backed Therapy Improves Outcomes For Cisplatin-Ineligible Bladder Cancer Patients

On Tuesday, Merck Co. Inc. (NYSE:MRK) released topline results from the Phase 3 KEYNOTE-905 trial (also known as EV-303) in patients with muscle-invasive bladder cancer (MIBC) who are ineligible for cisplatin-based chemotherapy.

Benzinga

FDA May Not Renew Pfizer's Authorization For Covid Shots In Younger Children, Moderna Prepares To Boost Supply

View Preview

Benzinga

RFK Jr has slashed vaccine research. You need to know how perilous that is for the world

The avian flu virus is now just one mutation away from easier transmission among humans. Trump’s health chief is a grave risk to world health, says Prof Devi Sridhar, chair of global public health at the University of Edinburgh

The Guardian - UK

Pfizer Covid vaccine for young children may not be renewed by FDA

Email obtained by Guardian says Pfizer was told approval may not be granted, meaning Moderna may have to fill gap

The Guardian - US

FTSE 100 edges down despite hopes of end to Russia-Ukraine war

Evening Standard

GSK to be paid up to £370 million after patent row settles in US

CureVac – a German pharmaceutical company – settled a long-running patent dispute with rival BioNTech and Pfizer in the US on Thursday.

Evening Standard

Get all your
news in one place.

100’s of premium titles.
One news app.

We Got This Covered

Former Trump official calls Kennedy’s latest move a ‘huge strategic misstep’ that ‘deeply compromises national security’

What Kennedy just canceled will terrify you.

Roll Call

HHS phases out mRNA vaccine trials for COVID-19, bird flu - Roll Call

HHS says the elimination of 22 mRNA vaccine development projects for COVID-19 and bird flu signals a shift in vaccine priorities.

Benzinga

Trump Tweets Trigger Stock Swings For Tesla, Boeing, Pfizer—And An Insider Trading Inquiry

When President Donald Trump hits "post" on Truth Social, Wall Street braces for impact.

Benzinga

RFK Jr. Halts $500 Million In mRNA Vaccine Projects Backed By Pfizer, Moderna: 'We're Prioritizing Safer, Broader Strategies'

The Department of Health and Human Services will cancel 22 vaccine development projects totaling $500 million, marking a major policy shift under Secretary Robert F. Kennedy Jr. that directly affects pharmaceutical giants like Pfizer Inc. (NYSE:PFE) and Moderna Inc. (NASDAQ:MRNA).

Get all your
news in one place.

100’s of premium titles.
One news app.

The Independent UK

Pfizer CEO says pharmaceutical companies want to work with Trump to make medicine more affordable

IN FULL

The Independent UK

‘We will work collaboratively’: Big Pharma admits it is discussing Trump’s plan to lower drug prices

Pfizer CEO says drugmakers ‘are all ready to roll up their sleeves and execute’ as president demands more direct-to-consumer options

Euronews

Pfizer posts strong earnings despite Trump’s new 'up to 250%' tariff threat

Pfizer beat earnings expectations and improved its outlook for the rest of the year, despite fresh statements from Trump announcing pharma tariffs next week.

Benzinga

Pfizer Cost-Cut Initiatives More Than Offset Tariffs Impact, Raises Outlook

On Tuesday, Pfizer Inc. (NYSE:PFE) reported second-quarter 2025 adjusted earnings of 78 cents, compared to 60 cents a year ago, beating the consensus of 57 cents.

Benzinga

Dow Surges Over 100 Points; Pfizer Earnings Top Views

U.S. stocks traded higher this morning, with the Dow Jones index gaining more than 100 points on Tuesday.

Barchart

Stock Index Futures Gain on Strong Earnings and Fed Rate-Cut Bets

September S&P 500 E-Mini futures (ESU25) are up +0.24%, and September Nasdaq 100 E-Mini futures (NQU25) are up +0.30% this morning, extending a rebound driven by bets on Federal Reserve interest rate cuts and solid corporate earnings.

Benzinga

Caterpillar, Pfizer And 3 Stocks To Watch Heading Into Tuesday

With U.S. stock futures trading higher this morning on Tuesday, some of the stocks that may grab investor focus today are as follows:

1 … 5 6 7 8

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.